Issue: February 2021
Source: Healio interview
Disclosures: Afzali reports acting as a consultant for AbbVie, Celgene, Janssen, Takeda and UCB; and receiving speaker fees from AbbVie, Janssen, Pfizer, Takeda and UCB.
December 29, 2020
1 min watch
Save

VIDEO: ‘Exciting’ therapies in the pipeline for IBD

Issue: February 2021
Source: Healio interview
Disclosures: Afzali reports acting as a consultant for AbbVie, Celgene, Janssen, Takeda and UCB; and receiving speaker fees from AbbVie, Janssen, Pfizer, Takeda and UCB.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this exclusive video, Anita Afzali, MD, director of the inflammatory bowel disease center at The Ohio State University, discusses the impact of emerging therapies in IBD.

In addition to filling in some of the unmet needs in IBD care, Afzali said new therapies could help physicians provide a more personalized approach for their patients.